Merck & Co. Expands U.S. Manufacturing with $70 Billion Investment

On October 20, 2025, Merck & Co. announced a significant investment of up to $70 billion aimed at expanding its domestic manufacturing capabilities in the United States. This initiative follows President Donald Trump's call for pharmaceutical companies to relocate their operations back to the U.S. to reduce reliance on foreign imports, particularly from China and India. The centerpiece of this expansion is a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility being constructed at Merck's Elkton, Virginia site, which will serve as a Center of Excellence for Pharmaceutical Manufacturing.

Merck to spend $70 billion to expand domestic manufacturing in USMerck breaks ground on $3 billion center of excellence for pharma manufacturing in VirginiaMerck Begins Construction on $3 Billion Pharmaceutical Center of Excellence in Virginia

The Elkton facility is designed to enhance Merck's production of active pharmaceutical ingredients and small molecule medicines. The project is expected to create over 500 full-time jobs and approximately 8,000 construction-related positions. Virginia Governor Glenn Youngkin highlighted the project's significance, stating it marks a "giant leap forward for both America’s and Virginia’s life sciences sector." The investment in Elkton builds on Merck's nearly 85-year history in the region.

Merck breaks ground on $3 billion center of excellence for pharma manufacturing in VirginiaMerck Begins Construction on $3 Billion Pharmaceutical Center of Excellence in VirginiaMerck Significantly Boosts Virginia Expansion Investment to $3 Billion

In addition to the Elkton facility, Merck has committed nearly $6 billion in manufacturing investments across several states, including North Carolina, Delaware, and Kansas. Notable projects include a $1 billion facility in Durham, North Carolina, aimed at expanding vaccine production, and a $1 billion biologics center in Wilmington, Delaware. These initiatives are projected to create more than 1,600 new jobs across the U.S.

Merck Investing $3.5B in Rahway HQ, $3B in Elkton, Va.Merck to spend $70 billion to expand domestic manufacturing in USMerck Begins Construction on $3 Billion Pharmaceutical Center of Excellence in Virginia

Robert M. Davis, Merck's chairman and CEO, emphasized the importance of this investment for the company and the broader healthcare landscape, stating, “This investment helps advance our goal of providing new, innovative treatment options for people facing serious health challenges in the U.S. and around the world.” The National Association of Manufacturers (NAM) also praised the investment, linking it to pro-growth policies that encourage domestic manufacturing.

Merck Investing $3.5B in Rahway HQ, $3B in Elkton, Va.

While Merck's expansion has been largely welcomed, some critics argue that the push for reshoring manufacturing may not address underlying issues such as high production costs in the U.S. compared to overseas markets. Additionally, concerns have been raised about the sustainability of such large-scale investments in the face of fluctuating market demands.

Merck Investing $3.5B in Rahway HQ, $3B in Elkton, Va.

There are varying reports regarding the total number of jobs created by Merck's initiatives. While some sources cite over 48,000 construction-related jobs by 2029, others focus on the immediate job creation associated with specific facilities, leading to discrepancies in the overall employment impact.

Merck Investing $3.5B in Rahway HQ, $3B in Elkton, Va.

Merck's expansion is part of a broader trend in the pharmaceutical industry, with other companies like Eli Lilly and Johnson & Johnson also announcing significant investments in U.S. manufacturing. As Merck continues to develop its facilities, the company aims to strengthen its supply chain resilience and enhance its capacity to meet growing demand for critical treatments.

Merck Significantly Boosts Virginia Expansion Investment to $3 Billion